These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16293350)

  • 41. Identification of the structural requirements of the receptor-binding affinity of diphenolic azoles to estrogen receptors alpha and beta by three-dimensional quantitative structure-activity relationship and structure-activity relationship analysis.
    Demyttenaere-Kovatcheva A; Cronin MT; Benfenati E; Roncaglioni A; Lopiparo E
    J Med Chem; 2005 Dec; 48(24):7628-36. PubMed ID: 16302803
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
    Axe FU; Bembenek SD; Szalma S
    J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators.
    Honório KM; Garratt RC; Polikarpov I; Andricopulo AD
    J Mol Graph Model; 2007 Mar; 25(6):921-7. PubMed ID: 17055759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Towards predictive inhibitor design for the EGFR autophosphorylation activity.
    San Juan AA
    Eur J Med Chem; 2008 Apr; 43(4):781-91. PubMed ID: 17689836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacophore and docking-based combined in-silico study of KDR inhibitors.
    Pasha FA; Muddassar M; Neaz MM; Cho SJ
    J Mol Graph Model; 2009 Aug; 28(1):54-61. PubMed ID: 19447057
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 3D-QSAR CoMFA of a series of DABO derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors.
    de Brito MA; Rodrigues CR; Cirino JJ; de Alencastro RB; Castro HC; Albuquerque MG
    J Chem Inf Model; 2008 Aug; 48(8):1706-15. PubMed ID: 18671385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.
    Du J; Qin J; Liu H; Yao X
    J Mol Graph Model; 2008 Sep; 27(2):95-104. PubMed ID: 18436460
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
    Yi P; Fang X; Qiu M
    Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
    Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
    J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First CoMFA characterization of vesamicol analogs as ligands for the vesicular acetylcholine transporter.
    Szymoszek A; Wenzel B; Scheunemann M; Steinbach J; Schüürmann G
    J Med Chem; 2008 Apr; 51(7):2128-36. PubMed ID: 18324757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 3D-pharmacophore model for RXR(gamma) agonists.
    Dong A; Wei J; Gao Q
    Neurochem Int; 2009; 54(5-6):286-91. PubMed ID: 19121355
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computer design of bioactive compounds based on 3-D properties of ligands.
    Martin YC
    NIDA Res Monogr; 1993; 134():84-102. PubMed ID: 8289889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacophore design and database searching for selective monoamine neurotransmitter transporter ligands.
    Macdougall IJ; Griffith R
    J Mol Graph Model; 2008 Apr; 26(7):1113-24. PubMed ID: 18023378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors.
    Vaidya M; Weigt M; Wiese M
    Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Consensus adaptation of fields for molecular comparison (AFMoC) models incorporate ligand and receptor conformational variability into tailor-made scoring functions.
    Breu B; Silber K; Gohlke H
    J Chem Inf Model; 2007; 47(6):2383-400. PubMed ID: 17958410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of CoMFA models of affinity and selectivity to angiotensin II type-1 and type-2 receptors.
    Sköld C; Karlén A
    J Mol Graph Model; 2007 Jul; 26(1):145-53. PubMed ID: 17161636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
    Puntambekar DS; Giridhar R; Yadav MR
    Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
    Salum Lde B; Polikarpov I; Andricopulo AD
    J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of variable docking conditions and scoring functions on corresponding protein-aligned comparative molecular field analysis models constructed from diverse human protein tyrosine phosphatase 1B inhibitors.
    Taha MO; AlDamen MA
    J Med Chem; 2005 Dec; 48(25):8016-34. PubMed ID: 16335926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.